Free Trial
NASDAQ:SLRN

Acelyrin (SLRN) Stock Price, News & Analysis

$6.71
-0.19 (-2.75%)
(As of 07/24/2024 ET)
Today's Range
$6.55
$6.96
50-Day Range
$3.86
$7.06
52-Week Range
$3.67
$29.88
Volume
498,874 shs
Average Volume
1.09 million shs
Market Capitalization
$664.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

Acelyrin MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
90.8% Upside
$12.80 Price Target
Short Interest
Bearish
11.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Acelyrin in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$7 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.33) to ($4.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.38 out of 5 stars

Medical Sector

593rd out of 901 stocks

Pharmaceutical Preparations Industry

277th out of 426 stocks

SLRN stock logo

About Acelyrin Stock (NASDAQ:SLRN)

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

SLRN Stock Price History

SLRN Stock News Headlines

Former Hedge Fund Manager Issues Crash Prediction
Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.
Acelyrin, Inc. (SLRN)
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
Acelyrin Founder Steps Down as CEO
Former Hedge Fund Manager Issues Crash Prediction
Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.
ACELYRIN, INC. Announces Leadership Transition
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
See More Headlines
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
7/24/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SLRN
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.80
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+90.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-381,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.74 per share

Miscellaneous

Free Float
85,559,000
Market Cap
$664.47 million
Optionable
Optionable
Beta
2.56
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Ms. Melanie Gloria B.S.N. (Age 46)
    Chief Operating Officer
    Comp: $667.52k
  • Ms. Mina Kim (Age 50)
    CEO & Director
  • Mr. Gilbert M. Labrucherie J.D. (Age 52)
    CFO & Chief Business Officer
  • Mr. Tyler Marciniak
    Head of Investor Relations & Communications
  • Ms. Sanam Pangali J.D.
    Chief Legal Officer & Head of People
  • Dr. Paul M. Peloso M.D. (Age 66)
    M.Sc., Chief Medical Officer
  • Ms. Suzy Buckhalter CPA
    Senior Director of Finance & Accounting
  • Mr. Kenneth A. Lock (Age 50)
    Chief Commercial Officer
  • Dr. Shephard Mpofu M.D.
    Chief Medical Officer
  • Ms. Patricia A. Turney (Age 57)
    Chief Technical Operations Officer

SLRN Stock Analysis - Frequently Asked Questions

How have SLRN shares performed this year?

Acelyrin's stock was trading at $7.46 on January 1st, 2024. Since then, SLRN stock has decreased by 10.1% and is now trading at $6.71.
View the best growth stocks for 2024 here
.

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.57.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an IPO on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

Who are Acelyrin's major shareholders?

Top institutional shareholders of Acelyrin include Nisa Investment Advisors LLC (0.01%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston.
View institutional ownership trends
.

How do I buy shares of Acelyrin?

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLRN) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners